Stay updated on RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma
Sign up to get notified when there's something new on the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page.

Latest updates to the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page
- CheckyesterdayChange DetectedA notice was added explaining that NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check8 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedThe footer’s site revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check36 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, blocking access to the clinical trial information. The error page shows a minimal header and a standard 403 message indicating restricted access.SummaryDifference18%

- Check57 days agoChange DetectedRevision: v3.6.6 has been added, replacing the previous Revision: v3.6.5 on the page. This reflects a minor update to the page’s version and does not indicate changes to the study data.SummaryDifference0.1%

- Check64 days agoChange DetectedThe study status is updated to Active, not recruiting, with a note that no longer looking for participants and updated last-updated dates; several study contact details were removed from the page.SummaryDifference3%

Stay in the know with updates to RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma
Enter your email address, and we'll notify you when there's something new on the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page.